The Royal Pharmaceutical Society (RPS) has re-elected Andrew Carruthers as chair of RPS Scotland Pharmacy Board.
Andrew is a Medicines Governance pharmacist within NHS Greater Glasgow and Clyde, where he has a clinical commitment to Care of the Elderly. Prior to becoming a
pharmacist, he studied Pharmacology at the University of Glasgow, and maintains a keen interest in pharmacokinetics and research.
In his address for the position, he said: "In my second term I want to continue to support and drive the introduction of RPS Ambassadors and the creation of an
online RPS community."
"As a previous RPS local coordinator, I've seen first-hand that RPS Local events are a great forum to formally support the training and development of local
pharmacists. With input from our members and RPS staff we could share learning, inspire, and enable development, and build a supportive online community for the
profession."
He was the RPS Local Co-ordinator for Greater Glasgow and Clyde for 3 years, then he co-opted on to the Scottish Pharmacy Board (SPB) in 2018 and have been an
active and effective member of the board. He was re-elected to the board in 2021 and he stood and was elected as Chair.
The British Generic Manufacturers Association (BGMA) has elected Diane DiGangi Trench to be its new vice-chair.
DiGangi Trench takes up the position replacing Xiromed's Peter Ballard and in 12-months' time will assume the association's chair role from Accord's Peter Kelly.
With over 25 years of pharmaceutical industry experience, DiGangi Trench has held a number of senior commercial roles including stints with Takeda and Astra Zeneca.
She joined Sandoz in 2018 in the US, where she served as Vice-President, Market Access and Patient Services.
In 2021, she became the head of Sandoz' UK business and in her two years in role, she has led the organisation through a post-COVID recovery and growth phase to
prepare for the proposed spin out of the company from its parent, Novartis, expected later this year.
She said: "It's a great honor to take on the role of Vice Chair of the BGMA. The success of the generics and biosimilar industry is essential to the functioning of
the NHS. Generic medicines fill four out of five UK prescriptions and biosimilars enable the NHS to expand access to more patients. I am passionate about increasing
the sustainability of our industry so we can continue to play our vital part in the health of the nation."
Mark Samuels, BGMA chief executive, said: "We are extremely fortunate to be able to call upon the expertise of Diane who has already added significant value through
her role on the BGMA board and leadership of a key strategic committee.
The General Pharmaceutical Council (GPhC) Fitness to Practise Committee decided to remove a pharmacist from the GPhC Register at a 'remote videolink' hearing
held on 13 - 14 April.
"The decision will not take effect until 12 May 2023 or, if an appeal is lodged, once that appeal has been concluded," the committee said.
Kapil Ramesh Rabadia, a pharmacist first registered on 25 July 2011 with GPhC under registration number 2075823 was convicted of 'fraud by abuse of position' and
'being concerned in supplying controlled drugs' following a guilty plea on 13 September 2021.
He was sentenced to 12 months imprisonment for the fraud by abuse of position and six months in respect of supplying a 3 Class B drug. However, the interim suspension
set out in the decision takes effect immediately and will lapse when the removal decision takes effect or once any appeal is concluded.
Between May 2018 and June 2019, Kapil ordered codeine linctus and Phenergan in excess of 100 bottles of each for four men who threatened him with knives and guns.
The men told the pharmacist that he needed to continue to make the supplies or "there would be consequences" for him and his family.
The NHS claims that it's been able to save taxpayers £1.2 billion in just three years by procuring hundreds of hospital medicines at a better price.
The adoption of cheaper versions of a single drug - adalimumab - which is used to treat more than 45,000 patients with rheumatoid arthritis, inflammatory bowel
disease and psoriasis, has accounted for about one third of the savings.
After the exclusive patent on the drug - originally known as its brand name Humira - expired in 2018, the NHS struck cost-saving deals to bulk-buy generic versions,
which have the same quality, safety and efficacy of a branded one.
Since then, tens of millions of pounds have been saved by buying cheaper generic versions of other medicines for conditions ranging from severe skin infections to
aggressive blood cancers.
Four in five medicines prescribed in the NHS are now non-branded, helping the NHS to achieve significant savings while ensuring the continuity of high-quality
patient care.
NHS chief executive Amanda Pritchard said: "Smart deals by the NHS mean patients are getting the best medicines and taxpayers are getting best value.
Boris Johnson has picked Steve Barclay as the new health secretary following the resignation of Sajid Javid, who stepped down on July 5 after saying he had
lost faith in prime minister's leadership.
Barclay - who had served as chief of staff of the prime minister since February 2022 - was previously a junior health minister in 2018, responsible for NHS workforce
and finance, before serving as Brexit secretary, chief secretary to the Treasury, and chancellor of the duchy.
He is the fourth health secretary after Jeremy Hunt, Matt Hancock and Sajid Javid in the past five years.
In a statement on his appointment, Barclay said it was "an honour" to be take up the position, adding: "Our NHS and social care staff have showed us time and again -
throughout the pandemic and beyond - what it means to work with compassion and dedication to transform lives.
"This government is investing more than ever before in our NHS and care services to beat the Covid-19 backlogs, recruit 50,000 more nurses, reform social care and
ensure patients across the country can access the care they need."
Paul Rees MBE has joined the National Pharmacy Association (NPA) today (27 November) as its new Chief Executive.
Current NPA Chief Executive Mark Lyonette, who is retiring, will remain at the NPA for some weeks in order to ensure a smooth handover.
Previously, Paul has worked as the Chief Executive of the Royal College of Psychiatrists for the seven years.
On joining NPA, Paul said: "It is a great privilege and honour to take up the position of NPA Chief Executive. The association is the voice of independent
community pharmacy and is core to the sector's future success in England, Scotland, Wales and Northern Ireland.
"I am delighted that the NPA has placed its trust in me and I intend to deliver for NPA members, for the sector and for society at large, which relies on there
being a vibrant community pharmacy network in villages, towns and cities across the four nations of the UK."
When Paul's appointment was first announced in September, NPA Chair Nick Kaye said that they identified him as an "excellent fit for our organisation" after a
rigorous recruitment process, and also thanked Mark for his "great work as chief exec since 2018."
Dr Amanda Doyle has been appointed as NHS England as director of primary and community care.
Prior to her new role, Amanda had joined NHS England and NHS Improvement as North West Regional Director on 2 August 2021 and previously she was the Chief
Clinical Officer for West Lancashire Clinical Commissioning Group (CCG), Blackpool CCG and Fylde and Wyre CCG.
Amanda was also the Integrated Care System Lead for Lancashire and South Cumbria, leading a large health and care transformation programme across the patch.
She has been a GP for more than 20 years, practising in a large practice in a deprived area of Blackpool, which, in addition to primary medical services, provides a range of urgent care services for patients across the Fylde Coast.
Amanda was the Co-Chair of NHS Clinical Commissioners from 2013 to 2018.
She was Senior Responsible Officer for the primary care component of the Long Term Plan and was involved in the leadership of the health inequalities, prevention and personalisation elements.
The Pharmacists' Defence Association (PDA) has called on pharmacy employers and pharmacists organisations to make donations towards the Pharmacist Support charity in the new year.
The association has urged them to donate £1 per pharmacist employee or member to the charity group to increase its funding from 2022 onwards.
Pharmacist Support, an independent charity, provides a variety of support services to pharmacists and their families, former pharmacists and pharmacy students in Great Britain.
It provides support through twelve sessions of fully funded counselling topharmacists, students, or trainees.
Since 2018, the association has donated more than £150,000 to the charity, in turn supporting its members who additionally seek assistance from Pharmacist Support.
Britain's GlaxoSmithKline will receive $1.25 billion (about £921 million) from Gilead Sciences as part of a settlement between its HIV medicines unit and the
US-based drugmaker, ending a long-drawn patent dispute.
The settlement, announced by GSK on Tuesday (February 1), relates to Gilead's antiretroviral drug Biktarvy, a medicine used to check the AIDS-causing virus, which
GSK said in 2018 infringed on its unit ViiV Healthcare's dolutegravir and other similar compounds.
HIV medicines developed by ViiV, in which Pfizer and Japan's Shionogi also hold small stakes, are a major part of GSK's plan to support its lagging pharmaceuticals business as it readies to spin off its consumer healthcare arm.
The payment is expected to be made in the first quarter this year, London-listed GSK said. Gilead will also pay a 3 per cent royalty until 2027 on sales of Biktarvy and on future US sales of any product containing its main component.
McKesson UK's CEO Toby Anderson has stepped down from the role with immediate effect after over three years with the company.
Toby joined McKesson UK as CEO in September 2018 moving from health & beauty retailer A.S. Watson Group, where he spent 12 years in various roles. As CEO Asia
and Eastern Europe, Toby was responsible for a rapidly growing business with more than 3,300 stores - including 1,500 pharmacies.
Prior to that Toby spent 11 years in a number of senior roles with J. Sainsbury, the second largest grocery retailer in the UK, his last role being Head of Online.
Dominik Meüser from AURELIUS Group said: "We are extremely grateful for the commitment Toby has demonstrated over the years to help us achieve the McKesson vision of becoming the UK's leading healthcare organisation. His leadership, during a period of great uncertainty, has given us the solid foundations we can now build on
to deliver sustained success in the future.
The Department of Health and Social Care (DHSC) has published plans to amend current pharmacy legislation on dispensing errors and clarify how registered
pharmacies are governed.
The Department's response to a public consultation on rebalancing medicines legislation and pharmacy regulation programme first proposed in summer 2018 was
delayed due to Brexit and the Covid-19 pandemic.
The programme aims to clarify and strengthen the organisational governance arrangements of registered pharmacies, specifically to define and clarify the core
purpose of the Responsible Pharmacist and Superintendent Pharmacist roles.
It will also give the General Pharmaceutical Council (GPhC) powers to define in professional standards how those roles are fulfilled.
The Medicines and Healthcare products Regulatory Agency (MHRA) has advised 'no one should stop taking valproate without advice from their healthcare
professional.'
The latest data on the use of valproate in England revealed that in the last 6 months the number of pregnant women prescribed valproate in a 6-month period has
fallen from 68 women in April to September 2018, to 17 women in October 2021 to March 2022.
In light of concerns that the current regulatory requirements for safe use are not being consistently followed, the MHRA conducted a review of the available data
and asked for advice from the independent Commission on Human Medicines (CHM).
"The CHM has advised that no one under the age of 55 should be initiated on valproate unless two specialists independently consider and document that there is no
other effective or tolerated treatment," said MHRA.
"Where possible, existing patients should be switched to another treatment unless two specialists independently consider and document that there is no other effective
or tolerated treatment or the risks do not apply."
The Department of Health and Social Care (DHSC) will introduce new arrangements for the setting of Drug Tariff Category A reimbursement prices from April 2024.
Driven by ministers, DHSC's decision aims to equalise access to margin on Category A medicines and it's part of a series of drug reimbursement reforms proposed by
the department following a public consultation in 2019.
Currently, prices of medicines in Category A are subject to monthly adjustment. From 1 April 2024, these will be updated quarterly based on sales and volume data
obtained by DHSC under the Health Service Products (Provision and Disclosure of Information) Regulations 2018. The transition will conclude in July 2025 when the reimbursement prices will be exclusively determined by the new method.
Advance notice for contractors regarding the 'new arrangements' has been outlined on the NHSBSA website.
However, Community Pharmacy England (CPE) did not support the introduction of the changes at this time as pharmacies are currently grappling with "wider challenges"
and there is uncertainty about the potential impact of these changes on the already "turbulent" medicines supply chain
Challenges in accessing the NHS waiting list are pushing more and more people toward private-funded alternatives for access, diagnosis and treatment,
thereby increasing the demand for private health cover.
According to a report published by health data provider LaingBuisson, the demand for private health cover, including medical and dental insurance and cash plans,
has surged to its highest levels since 2008.
The UK's overall health cover market reached £6.7 billion in 2022, an increase of £385 million from the previous year.
During the period from 2020 to 2022, the market experienced annual growth rate of 6.1 per cent, a significant increase compared to the average annual growth rate
of 1.7 per cent observed between 2008 and 2019, the research found.
A total of 4.2 million people were subscribed to medical cover schemes in 2022. When dependents covered by these policies were included, the number reached
7.3 million - the highest count since 2008.
LaingBuisson's analysis showed that medical cover volumes were steady through most of the 2010s, but began to increase alongside rises in the NHS waiting list
from 2018.
Christie & Co has revealed that Islay Pharmacy, the only pharmacy on the Isle of Islay in Scotland, has been sold for the second time in six years.
The business, which single-handedly serves the island's population of circa 3,200 residents, has been purchased by a husband-and-wife team - Lisa and Simon
Simpson - from South Shields.
Previous owner small group operator, Sanjay Majhu, acquired Islay Pharmacy in April 2018 and grew its turnover from £530,000 to just under £700,000.
He listed it for sale along with Inveraray Pharmacy and Tarbert Pharmacy as part of his initiative to downsize his estate, according to the broker.
"We decided to sell as our strategy was to acquire only within a 100-mile radius of Glasgow and Islay would be more suited for owner-operators.
"Raise awareness of pharmacies as places of primary health care provision," advocates the International Pharmaceutical Federation (FIP), emphasising the
need for universal recognition of pharmacists as essential healthcare professionals.
Despite significant advancements in pharmacy practice, many policymakers and members of the public still view pharmacies primarily as commercial enterprises
rather than essential providers of healthcare services.
The FIP is leading a campaign to change this perception, advocating for pharmacies to be recognised as vital components of primary health care.
Primary health care is crucial for achieving "health for all."
In 2018, the Declaration of Astana saw governments recommit to strengthening primary health care to achieve universal health coverage.
FIP, a signatory to this declaration, has since been dedicated to enhancing the role and impact of pharmacies in primary health care.
Customs officials at Mundra port in Gujarat's Kutch district, India, recently seized approximately 6.8 million Tramadol tablets valued at Rs 110 crore
(around GBP 10.2 million).
The tablets were discovered in two export containers bound for Sierra Leone and Niger in West Africa.
Tramadol, an opioid pain medication, was classified as a psychotropic substance under the Narcotic Drugs and Psychotropic Substances Act (NDPS Act) in 2018 and
its export is now restricted.
This synthetic opioid drug has gained notoriety in recent times as the "Fighter Drug" after it was reported that ISIS fighters used it to stay awake for long
hours, said a PIB release on Monday.
It is reportedly in high demand in African nations like Nigeria, Ghana, etc.
The Mundra Customs seizure is one of the largest seizures of Tramadol since it was notified under the NDPS Act, said the release.
The British Medical Association (BMA) has urged non-GP partners and contractors, including pharmacists, nurses, and physiotherapists, to support their
"Protect Your Patients, Protect Your GP Practice" campaign, which was launched to protest changes to the 2024/25 GP contract.
GP contractors and partners across England have strongly opposed the modifications to the GMS contract, leading to an ongoing dispute with the NHS.
The BMA highlights that general practice in England currently receives just 6 pence of every NHS pound and an average GMS 'global sum' of £107.57 per registered
patient annually.
Since 2018/19, CPI erosion to the GMS contract has resulted in a loss of £659 million, or 6.6%. This financial strain has contributed to the closure or merger
of over 1,300 practices over the past decade.
To address these issues, the BMA is urging all GP contractors and partner members to vote YES in the GPC England non-statutory ballot, which will be open
until July 29.
Walgreens Boots Alliance (WBA) has officially announced that Sebastian James, the Managing Director of Boots, will be stepping down from his role to pursue
a new opportunity in the healthcare sector.
James has given notice to leave the company and will remain with Boots until November. The UK pharmacy giant has already begun the search for a new Managing Director.
James is set to take on the role of CEO at Veonet, a leading European chain of ophthalmology clinics.
During his tenure as Managing Director since 2018, James played a pivotal role in transforming Boots into the UK's leading health and beauty retailer.
He oversaw significant growth and innovation, achieving thirteen consecutive quarters of retail market share growth. Most recently, the company announced strong
Q3 results in June with growth across all categories.
A man has been sentenced to three and a half years in prison for illegally importing and distributing unlicensed medicines from India, the Middle East,
and the Far East.
Antoine Christopher Kolias, 31, received his sentence at Southwark Crown Court on 28 June after being found guilty of criminal activities in May.
The Medicines and Healthcare products Regulatory Agency's (MHRA) Criminal Enforcement Unit (CEU) led the investigation, dubbed Operation Bentley.
Kolias was discovered to be acting both as a distributor for an established unlicensed medicines dealer and running his own illicit business.
He was involved in the sale of sildenafil citrate, the active ingredient in Viagra, as well as Class C drugs including tramadol, zopiclone, and pregabalin between
2018 and 2019, and again between 2020 and 2021.